In view of all that has been discussed so far, we can conclude that ABRACL can be transcriptionally regulated by MYBL2 to promote the proliferative ability, relative migration rate, invasive ability, as well as EMT process of breast cancer cells. Here, ABRACL is linked to breast carcinoma.